Atavistik Bio raises $120M in Series B financing, led by Nextech Invest and The Column Group, to advance treatments for Hereditary Hemorrhagic Telangiectasia and myeloproliferative neoplasms.
Amount Raised
$120 Million
Round Type
Series B
CambridgeBiotechnologySoftwareHealth CareScience And EngineeringInvestors
Description
Atavistik Bio, a Cambridge, MA-based developer of selective allosteric small molecule therapeutics, raised $120M in Series B financing. The round was led by Nextech Invest and The Column Group with participation from Lux Capital and Regeneron Ventures. The company plans to advance its oral allosteric AKT1-selective inhibitor for HHT through clinical proof of concept. Their clinical trial for the HHT program is anticipated to begin in the first half of 2026.
Quick answer
Atavistik Bio raised $120 Million in a Series B round, dated December 21, 2025. Investors: Lux Capital, Regeneron Ventures, Nextech Invest and The Column Group. Atavistik Bio is based in Cambridge, Massachusetts, United States.
- How much did Atavistik Bio raise?
- Atavistik Bio raised $120 Million in a Series B round on December 21, 2025.
- Who invested in Atavistik Bio?
- Lux Capital, Regeneron Ventures, Nextech Invest and The Column Group are named as investors in this round.
- What does Atavistik Bio do?
- Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology.
- Where is Atavistik Bio based and how big is it?
- Atavistik Bio is based in Cambridge, Massachusetts, United States. Fundz records about 38 employees.
- Who are the decision-makers at Atavistik Bio?
- Fundz holds 1 contact at Atavistik Bio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Atavistik Bio that raised within 45 days of this round, from Fundz verified event records.
- Enveric Biosciences raised $1.5M on January 28, 2026.
- PulseAI raised an undisclosed amount (Seed) on January 12, 2026.
- ViCentra B.V raised $13M (Series D) on January 8, 2026.
- PrognomiQ raised $12M on January 2, 2026.
- Vyriad raised $25M (Series B) on December 23, 2025.
- MAIA Biotechnology raised $1.5M on December 22, 2025.
Who to call at Atavistik Bio, and when
A new round usually means Atavistik Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Atavistik Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Atavistik Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Atavistik Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Atavistik Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAtavistik Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.